EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof‐of‐concept results from the DECIDE ‐ CV clinical programme

Pedro Marques iD, Thomas A Mavrakanas iD, Julian Guida, Tara Gédéon, Anahita Emami, Abdulkhaliq Alaamiri, Daniel Ho, Elite Possik, Guang Zhang, Michael A Tsoukas iD, Abhinav Sharma iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15691 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Pedro Marques und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Cardiovascular Diseases, Diabetic Nephropathies. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim, Janssen Research and Development, Novo Nordisk Foundation Center for Basic Metabolic Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The management of patients with type 2 diabetes is asynchronous, i.e. not coordinated in time, resulting in delayed access to care and low use of guideline‐directed medical therapy (GDMT).

Methods

We retrospectively analysed consecutive patients assessed in the ‘synchronized’ DECIDE‐CV clinic. In this outpatient clinic, patients with type 2 diabetes and cardiovascular or chronic kidney disease are simultaneously assessed by an endocrinologist, cardiologist and nephrologist in the same visit. The primary outcome was use of GDMT before and after the assessment in the clinic, including sodium‐glucose cotransporter 2 inhibitors, glucagon‐like peptide 1 receptor agonists, renin‐angiotensin system blockers and mineralocorticoid receptor antagonists. Secondary outcomes included the baseline‐to‐last‐visit change in surrogate laboratory biomarkers.

Results

The first 232 patients evaluated in the clinic were included. The mean age was 67 ± 12 years, 69% were men and 92% had diabetes. In total, 73% of patients had atherosclerotic cardiovascular disease, 65% heart failure, 56% chronic kidney disease and 59% had a urinary albumin‐to‐creatinine ratio ≥30 mg/g. There was a significant increase in the use of GDMT:sodium‐glucose cotransporter 2 inhibitors (from 44% to 87% of patients), glucagon‐like peptide 1 receptor agonists (from 8% to 45%), renin‐angiotensin system blockers (from 77% to 91%) and mineralocorticoid receptor antagonists (from 25% to 45%) ( p < .01 for all). Among patients with paired laboratory data, glycated haemoglobin, urinary albumin‐to‐creatinine ratio and N‐terminal proB‐type natriuretic peptide levels significantly dropped from baseline ( p < .05 for all).

Conclusions

Joint assessment of patients with diabetes in a synchronized cardiometabolic clinic holds promise for enhancing GDMT use and has led to significant reductions in surrogate cardiovascular and renal laboratory biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicCardiovascular DiseasesDiabetic NephropathiesHumansMaleFemaleAgedMiddle AgedRetrospective StudiesProof of Concept StudyMineralocorticoid Receptor AntagonistsSodium-Glucose Transporter 2 InhibitorsDiabetic AngiopathiesAngiotensin Receptor AntagonistsGlycated HemoglobinBiomarkersNatriuretic Peptide, BrainGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

cardiovascular diseasediabetic nephropathyheart failurereal‐world evidencetype 2 diabetes

Substanzen

Mineralocorticoid Receptor AntagonistsSodium-Glucose Transporter 2 InhibitorsAngiotensin Receptor AntagonistsGlycated HemoglobinBiomarkersNatriuretic Peptide, BrainGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada.
  • DREAM-CV Lab, Centre for Outcomes Research, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.
  • Division of Cardiology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada.
  • Division of Endocrinology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada.

ORCID-Profile: Pedro Marques, Thomas A Mavrakanas, Michael A Tsoukas, Abhinav Sharma

Förderung

  • Boehringer Ingelheim
  • Janssen Research and Development
  • Novo Nordisk Foundation Center for Basic Metabolic Research

Zitieren

APA

Marques, P., Mavrakanas, T. A., Guida, J., Gédéon, T., Emami, A., Alaamiri, A., Ho, D., Possik, E., Zhang, G., Tsoukas, M. A., & Sharma, A. (2024). Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof‐of‐concept results from the DECIDE ‐ CV clinical programme. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15691

Vancouver

Marques P, Mavrakanas TA, Guida J, Gédéon T, Emami A, Alaamiri A, et al. Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof‐of‐concept results from the DECIDE ‐ CV clinical programme. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15691

BibTeX
@article{Marques2024,
  author = {Marques, Pedro and Mavrakanas, Thomas A and Guida, Julian and Gédéon, Tara and Emami, Anahita and Alaamiri, Abdulkhaliq and Ho, Daniel and Possik, Elite and Zhang, Guang and Tsoukas, Michael A and Sharma, Abhinav},
  title = {Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof‐of‐concept results from the DECIDE ‐ CV clinical programme},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15691}
}
Kostenlos starten →